Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTR Nektar Therapeutics

Market Closed 07-17 16:00:00 EDT

68.26

+1.21

+1.80%

盘后67.82

-0.44-0.64%

17:36 EDT

High68.84	Low65.81	Vol538.40K
Open66.46	D1 Closing67.05	Amplitude4.52%
Mkt Cap2.30B	Tradable Cap1.99B	Total Shares33.74M
T/O36.52M	T/O Rate1.85%	Tradable Shares29.14M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTR","market":"US","secType":"STK","nameCN":"Nektar Therapeutics","latestPrice":68.26,"timestamp":1784318400000,"preClose":67.05,"halted":0,"volume":538398,"hourTrading":{"tag":"盘后","latestPrice":67.82,"preClose":68.26,"latestTime":"17:36 EDT","volume":17067,"amount":1164900.16,"timestamp":1784324212397,"change":-0.44,"changeRate":-0.006446,"amplitude":0.006446},"delay":0,"changeRate":0.018046234153616822,"floatShares":29136100,"shares":33742100,"eps":-8.095877,"marketStatus":"Market Closed","change":1.21,"latestTime":"07-17 16:00:00 EDT","open":66.46,"high":68.8399,"low":65.81,"amount":36519340.363128,"amplitude":0.045189,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-8.095877,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784534400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":67.05,"preHourTrading":{"tag":"盘前","latestPrice":66,"preClose":67.05,"latestTime":"09:29 EDT","volume":1050,"amount":69633.51675,"timestamp":1784294998990,"change":-1.05,"changeRate":-0.01566,"amplitude":0.01044},"postHourTrading":{"tag":"盘后","latestPrice":67.82,"preClose":68.26,"latestTime":"17:36 EDT","volume":17067,"amount":1164900.16,"timestamp":1784324212397,"change":-0.44,"changeRate":-0.006446,"amplitude":0.006446},"volumeRatio":0.756666674236594,"impliedVol":0.7111,"impliedVolPercentile":0.3347},"requestUrl":"/m/hq/s/NKTR","defaultTab":"news","newsList":[{"id":"2652228406","title":"Nektar’s Phase 3 Eczema Bet: What Rezpegaldesleukin Could Mean for NKTR Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2652228406","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652228406?lang=en_us&edition=fundamental","pubTime":"2026-07-18 00:31","pubTimestamp":1784305895,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics ($NKTR) announced an update on their ongoing clinical study. Nektar Therapeutics is running a Phase 3 study called “A Phase 3 S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektars-phase-3-eczema-bet-what-rezpegaldesleukin-could-mean-for-nktr-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektars-phase-3-eczema-bet-what-rezpegaldesleukin-could-mean-for-nktr-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649643971","title":"Nektar Therapeutics (NKTR) Advances Autoimmune Pipeline, Is The Upside Already Priced In?","url":"https://stock-news.laohu8.com/highlight/detail?id=2649643971","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649643971?lang=en_us&edition=fundamental","pubTime":"2026-07-06 10:24","pubTimestamp":1783304690,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (NKTR) is back in focus after positive mid stage data in alopecia areata and plans to start late stage trials in atopic dermatitis, raising questions about what the pipeline could mean for the stock.\nSee our latest analysis for Nektar Therapeutics.\nNektar Therapeutics’ recent 10.3% 1 day share price return to US$71.04 and 23.9% 1 month share price return suggest momentum has picked up again, alongside index inclusions and fresh enthusiasm around its autoimmune pipeline,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/nektar-therapeutics-nktr-advances-autoimmune-pipeline-is-the","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648463948","title":"Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Sells 5,681 Shares for $397,670","url":"https://stock-news.laohu8.com/highlight/detail?id=2648463948","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648463948?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:07","pubTimestamp":1783033645,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sells 5,681 shares for $397,670Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 5,681 common shares on June 30, 2026 at $70.He repor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL5p0X1l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky Sells 5,681 Shares for $397,670","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646360131","title":"Nektar Grants New Hires Options for 20,500 Shares at $60.98 Each Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2646360131","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646360131?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:30","pubTimestamp":1782505813,"startTime":"0","endTime":"0","summary":"Nektar grants new hires options for 20,500 shares at $60.98 each under inducement planNektar Therapeutics granted inducement equity awards to seven new hires on June 19, 2026 under its 2025 Inducement","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL6sWS6d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646609443","title":"Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646609443","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646609443?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:30","pubTimestamp":1782505800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nTUA2CFVNS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644347050","title":"Nektar Therapeutics CEO Robin Howard sells USD 1.2 million in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644347050","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644347050?lang=en_us&edition=fundamental","pubTime":"2026-06-19 07:09","pubTimestamp":1781824147,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics President and CEO W. Robin Howard sold 20,000 common shares on June 16-17.Sales priced at USD 59.97 to USD 61.65 per share.Direct holdings fell to 55,045 shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL74P0Ym:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nektar Therapeutics CEO Robin Howard sells USD 1.2 million in common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644788727","title":"Nektar Chief R&D Officer Jonathan Zalevsky sells 5,538 shares for $336,412.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2644788727","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644788727?lang=en_us&edition=fundamental","pubTime":"2026-06-18 07:13","pubTimestamp":1781738003,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics Chief R&D Officer Jonathan Zalevsky sold 5,538 common shares on June 15, 2026 at a weighted average USD 60.71.He held 15,437 common shares following the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDLZ2WSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nektar Chief R&D Officer Jonathan Zalevsky sells 5,538 shares for $336,412.98","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640718199","title":"Nektar grants inducement stock options for 11,900 shares at $69.49 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2640718199","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640718199?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:18","pubTimestamp":1780517934,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics granted non-qualified stock options for 11,900 shares to five newly hired employees under its 2025 Inducement Plan.Options were granted May 20, 2026 with an exercise price of $69.49 per share.Awards carry an eight-year term with four-year vesting: 25% after one year, then monthly vesting over the next three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire  on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDLd9GPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640181681","title":"Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640181681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640181681?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:15","pubTimestamp":1780517701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nTUA8RRSWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638631012","title":"Nektar Therapeutics to present at Jefferies Global Healthcare Conference via webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2638631012","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638631012?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:16","pubTimestamp":1779920184,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026.Management is scheduled for a webcast fireside chat at 1:20 p.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL12dqPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638952518","title":"Nektar Therapeutics interim CFO Linda M. Rubinstein files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2638952518","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638952518?lang=en_us&edition=fundamental","pubTime":"2026-05-27 06:20","pubTimestamp":1779834047,"startTime":"0","endTime":"0","summary":"Interim CFO Linda M. Rubinstein filed an initial Form 3 at Nektar Therapeutics covering her insider holdings as of May 15, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL6M3PjR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635717718","title":"Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nektar Therapeutics (NKTR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635717718","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635717718?lang=en_us&edition=fundamental","pubTime":"2026-05-14 20:30","pubTimestamp":1778761843,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IQVIA Holdings (IQV), BeOne Medicines (ONC) and Nekt...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-beone-medicines-onc-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-iqvia-holdings-iqv-beone-medicines-onc-and-nektar-therapeutics-nktr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0528227936.USD","LU1201861165.SGD","BK4588","LU1261432733.SGD","LU0477156797.USD","BK4137","MDCO","LU0198837287.USD","LU0130103400.USD","LU0648000940.SGD","BK4585","LU0128526141.USD","LU0882574055.USD","LU1791710400.SGD","LU1989764664.SGD","BK4530","HCSG","LU1989764748.USD","BK4526","BK4007","BK4121","LU0648001328.SGD","BK4581","LU0029874061.USD","LU1791710582.SGD","XLV","LU0130102774.USD","XBI","LU0130517989.USD","LU1201861249.SGD","ONC","LABU","LU0477156953.USD","NKTR","LU0130518102.USD","LU0980610538.SGD","IQV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635205563","title":"Assessing Nektar Therapeutics (NKTR) Valuation After Its Recent Share Price Recovery","url":"https://stock-news.laohu8.com/highlight/detail?id=2635205563","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635205563?lang=en_us&edition=fundamental","pubTime":"2026-05-13 14:54","pubTimestamp":1778655283,"startTime":"0","endTime":"0","summary":"Why Nektar Therapeutics (NKTR) is on investor radar\nNektar Therapeutics (NKTR) has drawn fresh attention after recent trading saw the stock move against a backdrop of mixed performance, with a modest gain over the past month but a stronger recovery across the past 3 months.\nSee our latest analysis for Nektar Therapeutics.\nAt a latest share price of $78.43, Nektar’s recent pullback over the past week contrasts with an 18.2% 3 month share price return and a very large 1 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/assessing-nektar-therapeutics-nktr-valuation-after-its-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nktr/nektar-therapeutics/news/assessing-nektar-therapeutics-nktr-valuation-after-its-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634620239","title":"Nektar price target lowered to $80 from $95 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2634620239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634620239?lang=en_us&edition=fundamental","pubTime":"2026-05-12 01:15","pubTimestamp":1778519719,"startTime":"0","endTime":"0","summary":"Wedbush analyst Martin Fan lowered the firm’s price target on Nektar (NKTR) to $80 from $95 and keeps a Neutral rating on the shares. The firm note...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nektar-price-target-lowered-to-80-from-95-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nektar-price-target-lowered-to-80-from-95-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119479642","title":"Stock Track | Nektar Therapeutics Plummets 5.13% Intraday After Wedbush Cuts Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=1119479642","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119479642?lang=en_us&edition=fundamental","pubTime":"2026-05-11 21:58","pubTimestamp":1778507911,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics' stock plummeted 5.13% during intraday trading on Monday, following a negative analyst action.The sharp decline came after investment firm Wedbush cut its price target on the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634281378","title":"Nektar Therapeutics Is Maintained at Neutral by Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2634281378","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634281378?lang=en_us&edition=fundamental","pubTime":"2026-05-11 20:38","pubTimestamp":1778503080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 11, 2026 08:38 ET (12:38 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634074283","title":"Nektar Therapeutics : Wedbush Cuts Target Price to $80 From $95","url":"https://stock-news.laohu8.com/highlight/detail?id=2634074283","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634074283?lang=en_us&edition=fundamental","pubTime":"2026-05-11 19:27","pubTimestamp":1778498831,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nFWN41O13C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NKTR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634495413","title":"Nektar Therapeutics Charts Aggressive Path With REZPEG","url":"https://stock-news.laohu8.com/highlight/detail?id=2634495413","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634495413?lang=en_us&edition=fundamental","pubTime":"2026-05-09 08:51","pubTimestamp":1778287866,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics (($NKTR)) has held its Q1 earnings call. Read on for the main highlights of the call. Nektar Therapeutics’ latest earnings call...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-charts-aggressive-path-with-rezpeg?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-charts-aggressive-path-with-rezpeg?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634498307","title":"Nektar Therapeutics Establishes New Equity Distribution Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2634498307","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634498307?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:21","pubTimestamp":1778278902,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics ( ($NKTR) ) has issued an update. On May 8, 2026, Nektar Therapeutics entered into an equity distribution agreement with Guggen...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-establishes-new-equity-distribution-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nektar-therapeutics-establishes-new-equity-distribution-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EQD","NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634295460","title":"Nektar Therapeutics Names Rubinstein New Interim CFO","url":"https://stock-news.laohu8.com/highlight/detail?id=2634295460","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634295460?lang=en_us&edition=fundamental","pubTime":"2026-05-09 06:20","pubTimestamp":1778278800,"startTime":"0","endTime":"0","summary":"Nektar Therapeutics named Linda Rubinstein as its next interim chief financial officer, effective May 15.Rubinstein, a partner of CFO services firm FLG Partners, succeeds Sandra Gardiner, who was also CFO on an interim basis and is a partner at FLG, according to a Friday filing with the Securities and Exchange Commission.Gardiner will be retiring and stepping down from the position at Nektar, which she has held since 2023, Nektar said.Rubinstein has been permanent and interim CFO of several public and private companies including Adverum Biotechnologies, Diasome, Five Prime, Ingenuity, iPierian, Kezar, and Tunitas.Nektar also said it entered an amendment to its consulting agreement with FLG, under which it will pay FLG $650 per hour for Rubinstein's services.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTR","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nektar.com","stockEarnings":[{"period":"1week","weight":-0.0298},{"period":"1month","weight":0.1205},{"period":"3month","weight":-0.1956},{"period":"6month","weight":0.8116},{"period":"1year","weight":1.5594},{"period":"ytd","weight":0.6145}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1835},{"period":"ytd","weight":0.09}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc.  The company was incorporated in 1990 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.53125,"avgChangeRate":0.03787},{"month":2,"riseRate":0.53125,"avgChangeRate":0.029488},{"month":3,"riseRate":0.40625,"avgChangeRate":-0.000642},{"month":4,"riseRate":0.46875,"avgChangeRate":0.016904},{"month":5,"riseRate":0.34375,"avgChangeRate":-0.004399},{"month":6,"riseRate":0.424242,"avgChangeRate":0.026471},{"month":7,"riseRate":0.424242,"avgChangeRate":-0.019637},{"month":8,"riseRate":0.46875,"avgChangeRate":0.044887},{"month":9,"riseRate":0.5,"avgChangeRate":0.042479},{"month":10,"riseRate":0.375,"avgChangeRate":-0.023288},{"month":11,"riseRate":0.6875,"avgChangeRate":0.087128},{"month":12,"riseRate":0.59375,"avgChangeRate":0.015542}],"exchange":"NASDAQ","name":"Nektar Therapeutics","nameEN":"Nektar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nektar Therapeutics,NKTR,Nektar Therapeutics股票,Nektar Therapeutics股票老虎,Nektar Therapeutics股票老虎国际,Nektar Therapeutics行情,Nektar Therapeutics股票行情,Nektar Therapeutics股价,Nektar Therapeutics股市,Nektar Therapeutics股票价格,Nektar Therapeutics股票交易,Nektar Therapeutics股票购买,Nektar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nektar Therapeutics(NKTR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nektar Therapeutics(NKTR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}